UK markets close in 37 minutes

ABIVAX Société Anonyme (AAVXF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
9.550.00 (0.00%)
As of 10:51AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close9.55
Open9.55
Bid0.00 x 0
Ask0.00 x 0
Day's range9.55 - 9.55
52-week range8.10 - 39.70
Volume2,020
Avg. volume125
Market cap171.041M
Beta (5Y monthly)1.50
PE ratio (TTM)N/A
EPS (TTM)-2.59
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    ABIVAX ANNOUNCES AD HOC ORDINARY AND EXTRAORDINARY GENERAL MEETING ON NOVEMBER 9, 2022

    EQS-News: ABIVAX / Key word(s): MiscellaneousABIVAX ANNOUNCES AD HOC ORDINARY AND EXTRAORDINARY GENERAL MEETING ON NOVEMBER 9, 2022 03.10.2022 / 18:00 CET/CESTThe issuer is solely responsible for the content of this announcement.ABIVAX ANNOUNCES AD HOC ORDINARY AND EXTRAORDINARY GENERAL MEETING ON NOVEMBER 9, 2022PARIS, FRANCE, October 3, 2022 – 6.00 p.m. (CEST) – Abivax (Euronext Paris: FR0012333284 – ABVX) (the “Company”), a phase 3 clinical-stage biotechnology company harnessing the immune sy

  • EQS Group

    ABIVAX ANNOUNCES THE RELEASE OF ITS 2022 HALF-YEAR FINANCIAL REPORT

    EQS-News: ABIVAX / Key word(s): Half Year ResultsABIVAX ANNOUNCES THE RELEASE OF ITS 2022 HALF-YEAR FINANCIAL REPORT 30.09.2022 / 18:00 CET/CESTThe issuer is solely responsible for the content of this announcement.ABIVAX ANNOUNCES THE RELEASE OF ITS 2022 HALF-YEAR FINANCIAL REPORTPARIS, France, September 30, 2022 – 06:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a phase 3 clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat

  • EQS Group

    ABIVAX ABSTRACT ON OBEFAZIMOD PHASE 2B RESULTS SELECTED FOR MODERATED POSTER PRESENTATION AT UEG WEEK 2022

    EQS-News: ABIVAX / Key word(s): MiscellaneousABIVAX ABSTRACT ON OBEFAZIMOD PHASE 2B RESULTS SELECTED FOR MODERATED POSTER PRESENTATION AT UEG WEEK 2022 27.09.2022 / 18:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Abivax abstract on obefazimod phase 2b results selected for moderated poster presentation at UEG Week 2022Obefazimod (ABX464) interim 48-week safety and efficacy analysis from the ongoing phase 2b maintenance study in moderate-to-severe ulcerative col